Efficacy and safety of topical 2% rebamipide ophthalmic suspension in dry eye disease at tertiary care centre
Indian Journal of Ophthalmology · 2023
DOI: 10.4103/ijo.ijo_2586_22 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Indian Journal of Ophthalmology, 2023. Verfasst von Kalpna Jain und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Sardar Patel Medical College, Bikaner, Rajasthan, India. Hauptthemen laut MEDLINE: Rose Bengal, Dry Eye Syndromes. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Purpose
To evaluate the effect and side effects of topical 2% rebamipide ophthalmic suspension in dry eye disease.
Method
This prospective randomized case control study included total 80 patients (40 cases and 40 controls) of dry eye. Symptoms were graded according to OSDI scoring system and specific tests for dry eye included Tear film breakup time (TBUT), Schirmer’s test, Fluorescein corneal staining (FCS), Rose Bengal staining) were performed. Case group received 2% rebamipide ophthalmic suspension four times daily and control group given carboxymethylcellulose 0.5% four times daily. The follow ups had done at two, six and twelve weeks.
Results
The maximum numbers of patients were between 45-60 years. Patient with mild moderate and severe OSDI Score shows marked improvement. Mild TBUT score showed improvement but statistically not significant ( P value-0.34). In moderate and severe TBUT Score statistically significant improvement ( P value- 0.0001, 0.0001). In all grade FCS shows statistically significant improvement with p value-0.0001, 0.0001, and 0.028 respectively. Schirmer’s test score in all cases had shown improvement but statistically not significant and P value were 0.09, 0.07, and 0.07 respectively. In mild, moderate and severe Rose Bengal staining statistically significant improvement ( P value -0.027, 0.0001, and 0.04) .The only side effect was dysgeusia (10% patients).
Conclusion
Rebamipide 2% ophthalmic suspension showed significant improvement in symptoms and signs of dry eye. It able to modify epithelial cell function, improve tear stability, and suppress inflammation suggests that it may be a first drug of choice for severe dry eye disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Sardar Patel Medical College, Bikaner, Rajasthan, India.
Zitieren
APA
Jain, K., Jaju, M., & Yadav, D. (2023). Efficacy and safety of topical 2% rebamipide ophthalmic suspension in dry eye disease at tertiary care centre. Indian Journal of Ophthalmology. https://doi.org/10.4103/ijo.ijo_2586_22
Vancouver
Jain K, Jaju M, Yadav D. Efficacy and safety of topical 2% rebamipide ophthalmic suspension in dry eye disease at tertiary care centre. Indian Journal of Ophthalmology. 2023. doi:10.4103/ijo.ijo_2586_22
BibTeX
@article{Jain2023,
author = {Jain, Kalpna and Jaju, Meenu and Yadav, Dinesh},
title = {Efficacy and safety of topical 2% rebamipide ophthalmic suspension in dry eye disease at tertiary care centre},
journal = {Indian Journal of Ophthalmology},
year = {2023},
doi = {10.4103/ijo.ijo_2586_22}
}
EUVIMED